Terms: = Breast cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
1273 results:
1. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
2. Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer.
Papakyriacou I; Kutkaite G; Rúbies Bedós M; Nagarajan D; Alford LP; Menden MP; Mao Y
Nat Commun; 2024 Apr; 15(1):3581. PubMed ID: 38678024
[TBL] [Abstract] [Full Text] [Related]
3. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
4. pd-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Kuboki Y; Koyama T; Matsubara N; Naito Y; Kondo S; Harano K; Yonemori K; Yoh K; Gu Y; Mita T; Chen X; Ueda E; Yamamoto N; Doi T; Shimizu T
Cancer Med; 2024 Apr; 13(8):e6980. PubMed ID: 38651187
[TBL] [Abstract] [Full Text] [Related]
5. Tumor-associated macrophage subtypes on cancer immunity along with prognostic analysis and SPP1-mediated interactions between tumor cells and macrophages.
Xu L; Chen Y; Liu L; Hu X; He C; Zhou Y; Ding X; Luo M; Yan J; Liu Q; Li H; Lai D; Zou Z
PLoS Genet; 2024 Apr; 20(4):e1011235. PubMed ID: 38648200
[TBL] [Abstract] [Full Text] [Related]
6. Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System.
Xiao H; Li X; Liang S; Yang S; Han S; Huang J; Shuai X; Ren J
ACS Nano; 2024 Apr; 18(17):11070-11083. PubMed ID: 38639726
[TBL] [Abstract] [Full Text] [Related]
7. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.
Gougis P; Hamy AS; Jochum F; Bihan K; Carbonnel M; Salem JE; Dumas E; Kabirian R; Grandal B; Barraud S; Coussy F; Hotton J; Savarino R; Marabelle A; Cadranel J; Spano JP; Laas E; Reyal F; Abbar B
JAMA Netw Open; 2024 Apr; 7(4):e245625. PubMed ID: 38630478
[TBL] [Abstract] [Full Text] [Related]
8. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-pd-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract] [Full Text] [Related]
9. OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS-STING pathway to mediate GBM immune escape.
Zhu W; Rao J; Zhang LH; Xue KM; Li L; Li JJ; Chen QZ; Fu R
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604814
[TBL] [Abstract] [Full Text] [Related]
10. Associations of pd-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
11. Harnessing pd-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy.
Hu N; Xue H; Zhang T; Fan Y; Guo F; Li Z; Huo M; Guan X; Chen G
Biomed Pharmacother; 2024 May; 174():116482. PubMed ID: 38520866
[TBL] [Abstract] [Full Text] [Related]
12. Evaluating immunotherapeutic outcomes in triple-negative breast cancer with a cholesterol radiotracer in mice.
Ciavattone NG; Guan N; Farfel A; Stauff J; Desmond T; Viglianti BL; Scott PJ; Brooks AF; Luker GD
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38502228
[TBL] [Abstract] [Full Text] [Related]
13. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D; Barve M; Vaishampayan U; Roda D; Calvo A; Jañez NM; Trigo J; Greystoke A; Harvey RD; Olszanski AJ; Opyrchal M; Spira A; Thistlethwaite F; Jiménez B; Sappal JH; Kannan K; Riley J; Li C; Li C; Gregory RC; Miao H; Wang S
Cancer Med; 2024 Mar; 13(5):. PubMed ID: 38501219
[TBL] [Abstract] [Full Text] [Related]
14. Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in mouse mammary tumor models.
Umer BA; Noyce RS; Kieser Q; Favis NA; Shenouda MM; Rans KJ; Middleton J; Hitt MM; Evans DH
PLoS One; 2024; 19(3):e0298437. PubMed ID: 38498459
[TBL] [Abstract] [Full Text] [Related]
15. The enhanced antitumor activity of bispecific antibody targeting pd-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract] [Full Text] [Related]
16. MGP
Chang K; Jiao Y; Zhang B; Hou L; He X; Wang D; Li D; Li R; Wang Z; Fan P; Zhang J
Int Immunopharmacol; 2024 Apr; 131():111818. PubMed ID: 38460300
[TBL] [Abstract] [Full Text] [Related]
17. Fucoidan enhances the anti-tumor effect of anti-pd-1 immunotherapy by regulating gut microbiota.
Li H; Dong T; Tao M; Zhao H; Lan T; Yan S; Gong X; Hou Q; Ma X; Song Y
Food Funct; 2024 Apr; 15(7):3463-3478. PubMed ID: 38456333
[TBL] [Abstract] [Full Text] [Related]
18. Combination of STAT3 inhibitor with Herceptin reduced immune checkpoints expression and provoked anti-breast cancer immunity: An in vitro study.
Jahangiri A; Ezzeddini R; Zounemat Kermani N; Bahrami F; Salek Farrokhi A
Scand J Immunol; 2023 Sep; 98(3):e13300. PubMed ID: 38441231
[TBL] [Abstract] [Full Text] [Related]
19. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract] [Full Text] [Related]
20. A Biodegradable Nanosuspension Locally Used for Inhibiting Postoperative Recurrence and Brain Metastasis of breast cancer.
Qian M; Jiang G; Guo W; Huang R
Nano Lett; 2024 Mar; 24(10):3165-3175. PubMed ID: 38426438
[TBL] [Abstract] [Full Text] [Related]
[Next]
